Gilead's Kite builds cell therapy manufacturing quickly even as Yescarta sales grow slowly

Gilead's Kite builds cell therapy manufacturing quickly even as Yescarta sales grow slowly

Source: 
Fierce Pharma
snippet: 

So far, Gilead Sciences' Kite Pharma has been buying from contractors the viral vector material needed for its chimeric antigen receptor T-cell (CAR-T) treatment Yescarta. But with an expanding pipeline of cell therapies, the company says it is time to be able to produce its own.